To the Editor:

Several large-scale studies indicate that factor V Leiden (FVL) is not associated with an increased risk of acute myocardial infarction (MI) in middle-aged or elderly populations.1-7However, Rosendaal et al8 have hypothesized that FVL might increase the risk of myocardial infarction among women less than 45 years of age, particularly in the subgroup of smokers. Specifically, in a study of 84 women with premature myocardial infarction, 8 were found to carry FVL (binomial 95% confidence interval [CI], 4.2% to 17.9%). In the subgroup of smokers who carried FVL, 7 of 62 were found to be carriers of FVL (binomial 95% CI, 4.6% to 21.9%). Based on these data and on an observed control prevalence of 4.1%, the investigators reported a 32-fold increased risk of MI among the subgroup of young female smokers who carried FVL as compared with nonsmokers free of the mutation.

To directly evaluate this hypothesis, we used polymerase chain reaction techniques to determine FVL status among 36 women in the Boston area who suffered a myocardial infarction before 45 years of age and compared the prevalence of this mutation with an age-, ethnicity-, and smoking-matched group of community-based controls, as well as with the mutation rate previously reported in a large-scale population-based study of FVL in the United States.9 

The average age of case subjects at the time of the MI was 39 years; 52% were smokers. As expected, case subjects were heavier, more likely to have a family history of premature atherothrombosis, and more likely to be treated for hypertension and hyperlipidemia, as compared with community-based controls.

We found no evidence in these data that FVL increased the risk of MI (Table 1). Specifically, of the 36 case subjects, 1 (2.7%) was heterozygous for FVL, as compared with 3 (8.3%) of the controls (P = .3). Similarly, the prevalence of the mutation in the case group (2.7%) was not statistically different from the 4.8% prevalence rate previously reported in a large-scale population-based study of American women free of any history of coronary disease (P = .6). Moreover, in the subgroup of smokers, only 1 of 19 (5.2%) case subjects with MI was found to carry FVL.

Table 1.

Factor V Leiden Among Women With MI Before 45 Years of Age and Two Control Populations

Case Subjects (n = 36) CommunityBased Controls (n = 36) PopulationBased Controls (n = 948)
FVL+  1 (2.7%)  3 (8.3%)  46 (4.8%) 
FVL−  35 (97%)  33 (92%)  902 (95%) 
 
 
 
Case Subjects (n = 36) CommunityBased Controls (n = 36) PopulationBased Controls (n = 948)
FVL+  1 (2.7%)  3 (8.3%)  46 (4.8%) 
FVL−  35 (97%)  33 (92%)  902 (95%) 
 
 
 

Thus, these data do not support the hypothesis that FVL is an important risk factor for MI among young women, regardless of smoking status.

To the Editor:

Myocardial infarction is a rare but devastating disease among young women. There are few studies available, and data on genetic risk factors are especially scarce. Therefore, the attempt of Amowitz et al to evaluate our findings in a new study is commendable. However, the size of their study (36 patients) makes it difficult to interpret their findings. This becomes clear when we look at the confidence intervals of their results and our results.

We studied 84 patients and 388 controls and found (with prevalences of carriership of factor V Leiden of 10% and 4%) a relative risk of 2.4, with a 95% confidence interval of 1.0 to 5.9.1-1 The risk was 25- to 32-fold increased in carriers with other major risk factors, as compared with noncarriers without other major risk factors. Amowitz et al report 1 carrier among 36 patients (2.7%) and 3 among 36 controls (8.3), which leads to a relative risk of 0.3, with a confidence interval of 0.01 to 4.20. From this we conclude that these data neither support nor refute our previous, larger study. The large discrepancy in the estimates of the carrier prevalence among controls (8.3% among 36 controls and 4.8% among 948 controls) illustrates the instability of estimates based on such small samples.

Recently, we have shown that another common prothrombotic mutation, the 20210 G to A variant of the protrombin gene, which is present in 2% to 4% of whites,1-2 increases the risk of myocardial infarction fourfold in young women1-3 and that the combination of the mutation with a major cardiovascular risk factor leads to a 43fold increased risk (compared with women with neither). A further analogy may be found in a large study among (mainly middleaged) men with myocardial infarction (560 patients and 646 controls), to which we found mildly elevated risks associated with both factor V Leiden and prothrombin 20210A and also more pronounced risks in the presence of other risk factors.1-4 We feel that the magnitude of these risks estimates and the analogies between the two abnormalities and the sexes indicate the associations to be real. Nevertheless, we too are interested in extending these findings, for which larger population-based studies are under way in Seattle and Leiden.

REFERENCES

1-1
Rosendaal
FR
Siscovick
DS
Schwartz
SM
Beverly
RK
Psaty
BM
Longstreth
WT
Jr
Raghunathan
TE
Koepsell
TD
Reitsma
PH
Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women.
Blood
89
1997
2817
1-2
Rosendaal
FR
Doggen
CJM
Zivelin
A
Arruda
VR
Aiach
M
Siscovick
DS
Hillarp
A
Watzke
HH
Bernardi
F
Cumming
AM
Preston
FE
Reitsma
PH
Geographic distribution of the 20210 G to A prothrombin variant.
Thromb Haemost
79
1998
706
1-3
Rosendaal
FR
Siscovick
DS
Schwartz
SM
Psaty
BM
Raghunathan
TE
Vos
HL
A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women.
Blood
90
1997
1747
1-4
Doggen
CJM
Manger Cats
V
Bertina
RM
Rosendaal
FR
Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A.
Circulation
97
1998
1037

L.L.A. is the recipient of a Clinical and Community Health Fellowship from Fleet Investment Management, Trustee of Charles A. King Trust.

1
Ridker
PM
Hennekens
CH
Lindpainter
K
Stampfer
MJ
Eisenberg
PR
Miletich
JP
Mutation in gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men.
N Engl J Med
332
1995
912
2
Van Bockxmeer
FM
Baker
RI
Taylor
RR
Premature ischaemic heart disease and the gene for coagulation factor V.
Nat Med
1
1995
185
3
Ardissimo
D
Peyvandi
F
Merlini
PA
Colombi
E
Mannucci
PM
Factor V (Arg506 → Gln) mutation in young survivors of myocardial infarction.
Thromb Haemost
75
1996
701
4
Emmerich
J
Poirier
O
Evans
A
Marques-Vidal
P
Arveiler
D
Luc
G
Aiach
M
Cambien
F
Myocardial infarction, Arg506 to Gln factor V mutation, and activated protein C resistance.
Lancet
345
1995
321
5
März
W
Seydewitz
H
Winkelmann
B
Chen
M
Nanuck
M
Witt
I
Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease.
Lancet
345
1995
526
6
Kontula
K
Ylikorkala
A
Miettinen
H
Vuoris
A
Kauppinen-Mäkelin
R
Hämäliänen
L
Palomäki
H
Kaste
M
Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction.
Thromb Haemost
73
1995
558
7
Cushman
M
Rosendaal
FR
Psaty
BM
Cook
EF
Valliere
J
Kuller
LH
Tracy
RP
Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: Results from the Cardiovascular Health Study.
Thromb Haemost
79
1998
912
8
Rosendaal
FR
Siscovick
DS
Schwartz
RK
Beverly
BM
Psaty
WT
Longstreth
WT
Raghunathan
TE
Koepsell
TD
Reitsma
PH
Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women.
Blood
89
1997
2817
9
Ridker
PM
Miletich
JP
Hennekens
CH
Buring
JE
Ethnic distribution of factor V Leiden in 4047 men and women: Implications for venous thromboembolism for venous thromboembolism screening.
JAMA
277
1997
1305
Sign in via your Institution